	US 12,263,177 B2
	Biologically active ganoderma lucidum compounds and synthesis of anticancer derivatives; ergosterol peroxide probes for cellular localization
Michelle M. Martinez-Montemayor, San Juan, PR (US); and Fatima Rivas, Germantown, TN (US)
Assigned to UNIVERSIDAD CENTRAL DEL CARIBE, Bayamón, PR (US); and ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., Memphis, TN (US)
Appl. No. 17/428,812
Filed by UNIVERSIDAD CENTRAL DEL CARIBE, Bayamón, PR (US); and ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., Memphis, TN (US)
PCT Filed Feb. 6, 2020, PCT No. PCT/US2020/017053 § 371(c)(1), (2) Date Aug. 5, 2021, PCT Pub. No. WO2020/163626, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,525, filed on Feb. 7, 2019.
Prior Publication US 2022/0125805 A1, Apr. 28, 2022
Int. Cl. A61K 31/575 (2006.01); A61K 36/074 (2006.01); A61K 47/20 (2006.01); A61P 35/00 (2006.01); G01N 33/58 (2006.01)

CPC A61K 31/575 (2013.01) [A61K 36/074 (2013.01); A61K 47/20 (2013.01); A61P 35/00 (2018.01); G01N 33/582 (2013.01)]

13 Claims

1. A method of modifying a cancer-related symptom in a subject, said method comprising the step of administering a pharmaceutical composition comprising a Ganoderma lucidum derivative to the subject, wherein the pharmaceutical composition modifies the cancer-related symptom, and wherein the Ganoderma lucidum derivative is selected from the group consisting of ergosterol sulfonamide, 5-6-dihydroergosterol sulfonamide, ergosterol peroxide sulfonamide, and any combination thereof.